<table id="table16" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 16: Response to PREZISTA/ritonavir 600/100 mg Twice Daily by Baseline Number of IAS-Defined Primary PI Resistance-Associated Substitutions: As-treated Analysis of Studies TMC114-C213, TMC114-C202, and TMC114-C215</caption>
<col align="center" span="1" valign="top" width="25%"></col>
<col align="center" span="1" valign="top" width="25%"></col>
<col align="center" span="1" valign="top" width="25%"></col>
<col align="center" span="1" valign="top" width="25%"></col>
<tbody>
<tr>
<th colspan="1"></th>
<th colspan="3">Studies TMC114-C213, TMC114-C202, TMC114-C215<br/>&lt; 50 copies/mL at Week 96<br/>N=439</th>
</tr>
<tr>
<th colspan="1"># IAS-Defined Primary PI Substitutions</th>
<th colspan="1">Overall</th>
<th colspan="1">De Novo ENF</th>
<th colspan="1">Re-Used/<br/>No ENF</th>
</tr>
<tr>
<td>
<content stylecode="bold">All</content>
</td>
<td>44% (192/439) </td>
<td>54% (61/112)</td>
<td>40% (131/327)</td>
</tr>
<tr>
<td>
<content stylecode="bold">0 – 4</content>
</td>
<td>50% (162/322)</td>
<td>58% (49/85)</td>
<td>48% (113/237)</td>
</tr>
<tr>
<td>
<content stylecode="bold">5</content>
</td>
<td>22% (16/74)</td>
<td>47% (9/19)</td>
<td>13% (7/55)</td>
</tr>
<tr>
<td>
<content stylecode="bold">≥ 6</content>
</td>
<td>9% (3/32)</td>
<td>17% (1/6)</td>
<td>8% (2/26)</td>
</tr>
</tbody>
</table>